Our pharmaceutical activities are focused around manufacturing APIs and excipients. Since 1946 we have been producing vitamin D and have meanwhile developed a range of vitamin D analogs and metabolites which are used as APIs in drugs. We also produce a pharmaceutical-grade cholesterol which is used as an excipient in liposomal drug delivery systems.
We have recently expanded our focus into contract research and manufacturing activities by investing in a production laboratory. This modern facility allows us to perform CRAMs activities for third parties on a small scale, focusing on highly potent APIs. In this facility we can work with substances that fall into the highest classes of containment, employing our recently acquired barrier isolater equipment.
CRAMs service on highly potent APIs
Since the Dishman Group has a history and experience in producing highly potent APIs, the facility in the Netherlands complements the group’s activities. Focused on small-scale production ranging from 100mg up to 10kg, we offer our production capabilities in a FDA-inspected facility to support clinical phase work as well as commercial production. A team of process experts, chemists and analytical experts offer development and optimisation of synthesis routes to support early phase development work.
Supported by strong project management skills and cross functional teams, Dishman has the ability to do in-company up-scaling and technology transfers using our network of production locations around the globe. By using our production locations in the Netherlands, the UK, Switzerland, China, Saudi Arabia and India we can offer the right size equipment and process conditions to supply the required API in every phase of the drug development process, from early phase development up to multi-ton commercialisation.
Vitamin D analogs and metabolites
Our programme of vitamin D analogs consists of the natural-occurring metabolites of vitamin D following the systhesis route in the human body. These compounds, calcitriol and calcifediol, are complemented by vitamin D analogs alfacalcidol, DHT-2, paricalcitol and doxercalciferol.
Vitamin D analogs and metabolites are used as active substances to treat or cure a range of conditions, including psoriasis, hyperparathyroidism and multiple sclerosis, and are used in trials to find cancer treatment.
The vitamin D analogs are produced in the Netherlands in a dedicated facility, which has been inspected by the FDA, and are supported by relevant regulatory registrations. The products are delivered to order and the packing is tailored to the batch size of the user.
Vitamin D2 and D3 production
The production of vitamin D2 and vitamin D3 has been a core activity of Dishman Netherlands. As early as 1920, vitamin D2 was being produced and in 1946 the production of vitamin D3 started.
The pharmaceutical product range includes the pure crystalline form of vitamin D3 as well as several formulations of vitamin D3 in oil and powder to allow easy downstream use of the vitamin.
We can offer custom-made formulations with a tailored activity per gram.
Cholesterol used in liposomal drug delivery systems
As a body own pre-cursor to vitamin D, cholesterol is an essential molecule in the human body. Its capability to form strong bonds in bi-lamellar systems and its behaviour in liquid crystalline matrixes make cholesterol an attractive molecule to use in liposomal drug delivery systems. These liposomal structures are (partly) stabilised by cholesterol, resulting in a prolonged survival time of the liposome intravenously or in a controlled release mechanism to slowly release the API.
The Dishman Group
Dishman Netherlands is part of the Dishman Group, which consists of Dishman Pharmaceuicals & Chemicals, Carbogen Amcis and Creapharm Parenterals. Headquarted in Ahmedabad, India, the Dishman Group has been active in the pharmaceutical market for decades and has built strong experience in research and manufacturing.